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Rho-kinase/myosin light chain 
kinase pathway plays a key role in 
the impairment of bile canaliculi 
dynamics induced by cholestatic 
drugs
Ahmad Sharanek1,2,*, Audrey Burban1,2,*, Matthew Burbank1,2, Rémy Le Guevel3, Ruoya Li4, 
André Guillouzo1,2 & Christiane Guguen-Guillouzo1,2,4
Intrahepatic cholestasis represents a frequent manifestation of drug-induced liver injury; however, 
the mechanisms underlying such injuries are poorly understood. In this study of human HepaRG 
and primary hepatocytes, we found that bile canaliculi (BC) underwent spontaneous contractions, 
which are essential for bile acid (BA) efflux and require alternations in myosin light chain (MLC2) 
phosphorylation/dephosphorylation. Short exposure to 6 cholestatic compounds revealed that BC 
constriction and dilation were associated with disruptions in the ROCK/MLCK/myosin pathway. At the 
studied concentrations, cyclosporine A and chlorpromazine induced early ROCK activity, resulting 
in permanent MLC2 phosphorylation and BC constriction. However, fasudil reduced ROCK activity 
and caused rapid, substantial and permanent MLC2 dephosphorylation, leading to BC dilation. The 
remaining compounds (1-naphthyl isothiocyanate, deoxycholic acid and bosentan) caused BC dilation 
without modulating ROCK activity, although they were associated with a steady decrease in MLC2 
phosphorylation via MLCK. These changes were associated with a common loss of BC contractions 
and failure of BA clearance. These results provide the first demonstration that cholestatic drugs alter 
BC dynamics by targeting the ROCK/MLCK pathway; in addition, they highlight new insights into the 
mechanisms underlying bile flow failure and can be used to identify new predictive biomarkers of drug-
induced cholestasis.
Intrahepatic cholestasis represents a frequent manifestation of drug-induced liver injury (DILI) in humans1. In 
several population-based studies of DILI, a cholestatic pattern and a mixed pattern were observed in 20–40% 
and 12–20% of the patients, respectively. The mortality rate in patients has been estimated as 7.8% in certain 
studies, although it can be lower (2.5%) in groups of patients with mixed hepatocellular and cholestatic dysfunc-
tion2. However, the primary problem associated with cholestasis is that accurately predicting its risk is extremely 
difficult3.
A frequently reported causal mechanism underlying cholestatic disease is hepatobiliary transporter system 
alterations, in particular alterations to the bile salt export pump (BSEP/ABC11), which is the most physiologi-
cally important canalicular bile transporter4. Bile acid (BA) transport and secretion can also be impaired by the 
inhibition of BA uptake and efflux across the sinusoidal membrane. Although many cholestatic drugs are known 
to inhibit BSEP, several others are ineffective5. Therefore, the low prediction rate of the disease suggests that 
drug-induced cholestasis is linked to prior intracellular events involving one or more signalling pathway(s) that 
remain to be identified.
Membrane transporter efficiency, intracellular trafficking and efflux dynamics are necessarily interconnected 
via complex mechanisms that converge in dynamic movements that control bile clearance and involve signalling 
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mechanisms that interfere with acto-myosin interactions. Rho GTPases play a critical role in actin distribution, 
which affects cytoskeleton organization and cell motility6. The RhoA/Rho-kinase (ROCK) pathway plays a major 
role in vasocontraction and vascular tone regulation7. Activation of the RhoA/ROCK pathway is also essential for 
the contraction of vascular smooth muscle8.
The first step for activating the RhoA/ROCK pathway involves G protein-coupled vasopressor receptors and con-
tractile agonists. These receptors activate the small monomeric GTPase RhoA, which activates ROCK and leads to 
MYPT1 phosphorylation and myosin light chain phosphatase (MLCP) inhibition, thereby resulting in the enhanced 
phosphorylation of myosin light chain (MLC). This phosphorylation catalyses interactions between the myosin head 
and actin and subsequently allows myosin ATPase to produce a sliding force that results in acto-myosin contraction9 
(Fig. 1). Myosin II contractile activity in smooth muscle and non-muscle cells is also stimulated through the phos-
phorylation of MLC by Ca2+/calmodulin (CaM)-dependent myosin light-chain kinase (MLCK)10.
Signalling pathways have been identified as fundamental mechanisms that control bile canaliculi (BC) forma-
tion. Previous studies have shown that the ROCK pathway plays a major role in establishing bile ductular polarity 
in hepatic cells11, whereas other studies have demonstrated that BAs stimulate canalicular network formation and 
maintenance via the cAMP-liver kinase-B1 and AMP kinase-dependent pathways by affecting the actin cytoskel-
eton via phosphorylation of MLC2 and tight junction assembly. This process occurs directly or indirectly through 
small GTPases, which alter the cellular energy status12–14. ROCK was also found to mediate the regulation of 
intrahepatic vascular tone in humans with cirrhotic livers and in rats with bile ductular ligation15. However, a 
direct contribution of the ROCK/MLCK pathway to intrahepatic BC disorders has not been described.
Polarized hepatocytes are essential for bile flow, and a loss of polarity causes bile secretory failure and cholestasis16. 
Primary human hepatocyte cultures, particularly in a collagen sandwich configuration (SCHH), form a multicellular 
canalicular network as existing in vivo17. The differentiated human HepaRG cell line, which expresses phase 1 and 2 
drug metabolizing enzymes and transporters and forms polarized structures with functional BC, was successfully used 
in the in vitro production of BAs that mimicked features of intrahepatic cholestasis induced by chlorpromazine (CPZ) 
and cyclosporine A (CsA) treatment and the characterization of mechanisms involved in the initiation of lesions18–20.
In this study, 6 compounds with diverse chemical structures were selected, and they all have the ability to 
induce BC deformations (Supplementary Table 1). These compounds include the cholestatic drugs CPZ, CsA 
and bosentan; the hepatotoxicant α –naphthyl isothiocyanate (ANIT), which is largely used in rodent mod-
els of human intrahepatic cholestasis and biliary function disruption, although the underlying mechanism 
remains unclear21; the Y-27632 ROCK inhibitor analogue fasudil, which is used in combination with bosentan 
for the treatment of pulmonary arterial hypertension; and the secondary BA deoxycholate (DCA). A previous 
study showed that DCA infusion in rats resulted in canalicular membrane structural alterations accompa-
nied by reduced excretory functions in the liver22. Using these cholestatic agents and taking advantage of the 
well-polarized HepaRG and human hepatocytes, we investigated whether the ROCK/MLCK pathway has a criti-
cal role in cytoskeleton rearrangement and the BC deformations that accompany cholestatic insults.
Results
Morphological alterations of BC induced by the tested compounds. Phase-contrast examinations 
and rhodamine-phalloidin fluoroprobe labelling of cytoskeletal F-actin showed that untreated differentiated 
HepaRG cells as well as conventional cultured human hepatocytes (CCHH) have large biliary pockets (saccular 
Figure 1. Schematic representation of MLC phosphorylation regulation by Rho-kinase and myosin light 
chain kinase. ROCK, Rho-kinase; Ca2+, calcium; CaM, calmodulin; MLCK, myosin light chain kinase; MLCP, 
myosin light chain phosphatase; MYPT-1, myosin phosphatase target subunit 1; MLC, myosin light chain, ET-1, 
endothelin-1; ETR, endothelin receptor; IP3, inositol 1,4,5-triphosphate; GPCR, G-protein coupled receptor; 
PKC, protein kinase C; PLCβ , phospholipase C β ; DAG, diacylglycerol; PI3K, phosphatidylinositol 3-kinases ; 
ERK, extracellular signal-regulated kinases; MAPK, mitogen-activated protein kinases ; GF , growth factor.
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lumen: S-BC) that branch out to smaller ductules (tubular lumen; T-BC) that usually occur in one extremity. In 
SCHH, however, most ductules are in a tubular form (T-BC) and form a network of connections. BC integrity 
was visualized by immunolocalization of the junctional zona occludens-1 protein (ZO-1), which co-localized 
with pericanalicular F-actin (Fig. 2A). Canalicular transporters, multidrug resistance protein 1 (MDR1/ABCB1) 
and multidrug-resistance-related protein 2 (MRP2/ABCC2), were correctly distributed on across the canalicular 
membranes. The accumulation of 5 (and 6)-carboxy-2′,7′-dichlorofluorescein (CDF) into the BC lumen con-
firmed the integrity as well as the activity up to the canalicular poles (Fig. 2A). Typical BC of different sizes closed 
by tight junctions were also observed under an electron microscope (Fig. 2B). These characteristics were similar 
in the three cell models (HepaRG cells, CCHH and SCHH).
A short exposure to the 6 cholestatic compounds was used to investigate the early events that led to BC defor-
mations in the three cell models. The toxicity of the 6 compounds was evaluated in HepaRG cells using the MTT 
test after a 4 h exposure (Fig. 3A). Non-toxic concentrations (50 μM each) of CPZ, CsA, fasudil and ANIT; 200 μM 
DCA; and 100 μM bosentan deformed most S-BC structures (Figs 3 and 4). Therefore, these concentrations were 
selected for further analysis. Phase-contrast imaging showed that exposure to CPZ or CsA resulted in the progres-
sive constriction of S-BC, whereas exposure to the other 4 compounds (i.e., fasudil, ANIT, DCA and bosentan) 
resulted in spectacular dilation of S-BC in both human HepaRG and primary hepatocytes. S-BC deformations 
were confirmed by rhodamine-phalloidin staining of pericanalicular F-actin (Figs 3B and 4) and localization of 
the junctional ZO-1 protein in HepaRG cells (Fig. 3B).
Associated dysfunctions of BC dynamics. Using time-lapse microscopy, the BC of untreated HepaRG 
hepatocytes revealed spontaneous rhythmic motility characterized by repeated opening and closing spikes every 
20–30 min (Fig. 5A; Supplementary video 1). These spikes allowed for the dynamic evacuation of products from 
the S-BC into the T-BC, which led to reductions in the S-BC lumen size (Fig. 5B). Comparisons with normal 
CCHH showed similar rhythmic movements (Fig. 5A–C). T-BC underwent contraction/relaxation cycles with 
no detectable spikes, which may have been related to the tubular nature of BC and the scarcity of S-BC in SCHH 
(Fig. 5A–D; Supplementary videos 2 and 3).
We further analysed the spike rhythms in the presence of the different compounds. For instance, within 1 h 
of the HepaRG cell treatment, CPZ induced permanent constriction of the S-BC, whereas fasudil had induced 
strong dilation (Fig. 6A,B). However, both treatments led to a static state of S-BC that was characterized by the 
total disappearance of spikes and a loss of connections between the S-BC and T-BC (Fig. 6A–D, Supplementary 
videos 4 and 5). The ZO-1 protein distribution was used to measure the BC areas. For example, 73% of the S-BC 
from the cell layers exposed to CPZ had lumen with a size ≤ 50 μm2 compared with 41% of the S-BC in untreated 
cells. However, in the presence of fasudil, up to 46% of the S-BC were ≥ 100 μm2 compared with only 13% in 
untreated cultures (Fig. 6E). These results indicated that alterations occurred in the majority of BC in HepaRG 
hepatocytes treated with cholestatic drugs.
Alteration of bile flow as a consequence of BC dynamic disorders. To demonstrate that contractile 
dynamic movements have serious consequences on bile flow activity, we used two labelled BAs, 3α -hydroxy-7-n
itrobenzoxadiazolyl-ursodeoxycholic acid (NBD-UDCA) fluorescent analogue and [3H]-TA, as well as CDFDA. 
When the control and treated HepaRG cells were exposed to NBD-UDCA or CDFDA, the effects of the com-
pounds on BA intracellular trafficking and efflux at the canalicular lumen could be detected. After incubation, 
fluorescent NBD-UDCA and CDF were found in the BC of untreated cells, whereas they were barely detected in 
the constricted BC of CPZ- and CsA-treated cells or in the large isolated BC cisternae induced by ANIT, DCA 
and bosentan. However, both fluorescent substrates accumulated in the isolated BC cisternae of fasudil-treated 
cells, although the clearance of BC was delayed compared with that of untreated cells (Fig. 7A). Indeed, a 2.7-fold 
higher number of CDF-positive BC were observed within 3 h in the fasudil-treated cells compared with that in 
the corresponding control cells (Fig. 7A,B). These results indicate a major failure in bile flow that was correlated 
with an abnormal morphology of BC and a loss of their dynamic movement induced by all of the cholestatic 
compounds.
All of the tested compounds induced an accumulation of [3H]-TA in the cell layers. A reduction in BA 
clearance to 43% (p < 0.0001), 13% (p < 0.0001), 49% (p = 0.0002), 32% (p < 0.0001) and 57% (p = 0.001) was 
observed with CPZ, CsA, fasudil, DCA and bosentan, respectively. Importantly, accumulations were not detected 
after the ANIT treatment (Fig. 7C).
A previous study23 showed that the addition of TA accelerated the frequency of BC contractions compared 
with that of untreated cells. Consistent with the increased dynamics of BC, TA loading increased the clearance 
of [3H]-TA in a dose-dependent manner to 157% (p = 0.02), 207% (p < 0.0001) and 216% (p < 0.0001) at 10, 50 
and 100 μM, respectively (Fig. 7D). Interestingly, the treatment with 50 μM CPZ and 50 μM fasudil lowered the 
TA-induced increase in [3H]-TA clearance to 55% (p = 0.0004) and 103% (p = 0.01), respectively, whereas the 
50 μM TA treatment presented a clearance of 215% (Fig. 7E).
Drug-induced bile flow failure is associated with the modulation of the ROCK pathway. ROCK 
has pleiotropic functions and primarily regulates cellular contraction, motility, morphology and polarity. We 
examined potential links between disorders of BC dynamics induced by the tested compounds and the ROCK 
pathway. Interestingly, BC dilation was observed in the presence of Y-27632 (20 μM), a specific ROCK inhibitor, 
indicating a role of ROCK in controlling the morphology of BC (Fig. 8A). Next, we analysed the effects of the 
tested compounds on ROCK activity after 1 h of treatment. At low concentrations, CPZ and CsA did not sig-
nificantly modify ROCK activity, whereas both compounds induced up to 2-fold increases of ROCK activity at 
doses that caused a constriction of BC. However, fasudil inhibited ROCK activity by 50% (p = 0.01) and caused a 
www.nature.com/scientificreports/
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Figure 2. Polarity of human HepaRG and primary hepatocytes. (A) Phase-contrast microscopy examination 
of the BC in HepaRG hepatocytes, CCHH and SCHH. Rhodamine-phalloidin fluoroprobe staining of 
pericanalicular F-actin (red); immunolocalization of the junctional ZO-1 protein (green). Merged images 
showing that the junctional ZO-1 protein (green) co-localizes with the pericanalicular F-actin (red) in HepaRG 
cells CCHH and SCHH. Immunolocalization of the hepatobiliary transporters MDR1 and MRP2 (green). 
CDF accumulation in BC (green). Hoechst-labelled nuclei (blue). Fluorescence images were obtained with 
a Cellomics ArrayScan VTI HCS Reader (bar = 30 μm). (B) Electron microscopy examination of the tight 
junctions surrounding BC in HepaRG cells (arrows) (bar = 10 μm).
www.nature.com/scientificreports/
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Figure 3. Cytotoxicity evaluation and alteration of the BC morphology by the tested compounds in 
HepaRG cells. (A) Cells were incubated for 4 h with different concentrations of CPZ (0–200 μM), CsA 
(0–200 μM), fasudil (0–200 μM), ANIT (0–200 μM), DCA (0–800 μM) and bosentan (0–400 μM). Cytotoxicity 
was measured by the MTT colorimetric assay. Data were expressed relative to the untreated cells, which 
were arbitrarily set at a value of 100%. Data represent the means ± SEM of three independent experiments. 
(B) Untreated cells and cells treated with 50 μM CPZ, 50 μM CsA, 50 μM fasudil, 50 μM ANIT, 200 μM DCA 
or 100 μM bosentan. Phase-contrast images were captured after 3 h; BC (arrows); F-actin localized using 
rhodamine-phalloidin fluoroprobe (red). Immunolabelling of the junctional ZO-1 protein (green) in HepaRG 
cells treated with the tested compounds compared with that of the control cells. Nuclei stained in blue (Hoechst 
dye). The images were obtained with a Cellomics ArrayScan VTI HCS Reader (bar = 30 μm).
www.nature.com/scientificreports/
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Figure 4. Alteration of the BC morphology by the tested compounds in CCHH and SCHH. Untreated cells 
and cells treated with 50 μM CPZ, 50 μM CsA, 50 μM fasudil, 50 μM ANIT, 200 μM DCA, or 100 μM bosentan. 
Phase-contrast images were captured after 3 h. F-actin was localized using a rhodamine-phalloidin fluoroprobe 
(red). Nuclei stained in blue (Hoechst dye). (bar = 30 μm).
www.nature.com/scientificreports/
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Figure 5. Dynamics of BC in human HepaRG and primary hepatocytes. (A) Time-lapse imaging showing 
unidirectional rhythmic opening (green arrows) and closing (red arrows) spikes associated with contraction/
relaxation of S-BC (white arrows). (B–D) Quantification of S-BC area in arbitrary units (A.U.) and graphic 
representation of spikes. Imaging was performed using an inverted microscope (bar = 10 μm), and video 
analysis was performed using a modelling tool (Tracker 4.87).
www.nature.com/scientificreports/
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Figure 6. Disruption of BC rhythmic movements in CPZ- and fasudil-treated HepaRG hepatocytes. 
(A,B) Representative time-lapse imaging of HepaRG cells treated with 50 μM CPZ or 50 μM fasudil for 4 h 
(bar = 10 μm). (C,D) Quantification of the S-BC area and spikes showing the early disappearance of rhythmic 
spikes (green/red arrows) with both drugs. Occurrence of permanent constriction of S-BC with CPZ and 
dilation with fasudil (white arrows). (E) Quantification of the BC area based on ZO-1 protein distribution (as 
in Fig. 3) using Cellomics ArrayScan VTI HCS Reader software as described in the Materials and Methods. The 
BC were grouped into 3 categories according to their area.
www.nature.com/scientificreports/
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Figure 7. Effects of the tested compounds on BA clearance. (A) NBD-UDCA and CDF efflux. White arrows 
indicate fluorescence in the BC (bar = 30 μm). (B) Quantification of CDF accumulation in the BC after fasudil 
treatment. (C,D) [3H]-TA clearance in the HepaRG cells treated for 2 h with either the tested compounds or 
different concentrations of unlabelled TA. (E) [3H]-TA clearance in the cells treated with either CPZ or fasudil 
or co-treated with unlabelled TA. The data were expressed relative to that of the untreated cells arbitrarily set at 
100%. The data represent the means ± SEM of 3 independent experiments. *p < 0.05 compared with that of the 
untreated cells, #p < 0.05 compared with that of TA (50 μM) alone.
www.nature.com/scientificreports/
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strong dilation of BC, which was expected. No significant ROCK inhibition was observed with ANIT, DCA and 
bosentan (Fig. 8B).
Drug-induced bile flow failure is associated with altered myosin II activation. Non-muscle myo-
sin II is an actin-based motor protein that is controlled by ROCK. Phosphorylation of MLC2, the regulatory 
subunit of myosin II, at serine-19 results in increased myosin ATPase activity and acto-myosin contractility24. 
We postulated that the dynamic movements of BC could be controlled by pericanalicular myosin activity. First, 
we used the myosin heavy chain ATPase inhibitor BDM (20 mM) and observed alterations of BC that led to 
their dilation, which was also observed with fasudil, ANIT, DCA, and bosentan (Fig. 9A). Further analysis of the 
phosphorylation state of MLC2 in the untreated cells demonstrated alternating regular phases of phosphorylation 
and dephosphorylation of MLC2 every 30–45 min, which were coordinated with BC spikes, indicating a role for 
myosin II in controlling BC dynamics (Fig. 9B,C). Treatment with the 6 tested compounds resulted in an impor-
tant disruption of the MLC2 phosphorylation/dephosphorylation rhythm. Treatment with CPZ and CsA induced 
permanent MLC2 phosphorylation and led to permanent constriction of the S-BC. However, fasudil drastically 
and permanently inhibited MLC2 phosphorylation and caused strong dilation of the BC. This phosphorylation/
dephosphorylation rhythm was also inhibited (although to a lesser extent) by ANIT, DCA and bosentan (Fig. 9C). 
A 2-fold increase in the MLC2 phosphorylation/dephosphorylation frequency was observed in the presence of 
TA, which was correlated with the increased S-BC contraction/relaxation frequency described above (Fig. 9B).
Both ROCK and MLCK are signalling targets of cholestatic compounds. Because MLCK is cou-
pled to ROCK and shares MLC2 as a common substrate, we evaluated whether MLCK also contributed to BC 
lumen alterations. In the presence of ML-9 (20 μM), a specific MLCK inhibitor, S-BC dilation was observed 
(Fig. 10A). Therefore, we hypothesized that although ANIT, DCA and bosentan do not have an effect on ROCK 
activity, they could act through MLCK inhibition. ANIT, DCA and bosentan alone increased the BC mean area 
by 1.9 (p < 0.0001), 1.56 (p = 0.0001) and 1.48 fold (p = 0.002) after 3 h of exposure, respectively. Co-treatment 
with calmodulin (CaM), a primary MLCK activator, counteracted the BC dilation induced by the 3 compounds, 
and CaM completely prevented the inhibition of [3H]-TA clearance induced by bosentan and DCA (Fig. 10D). 
Moreover, co-treatment with bosentan and ML-9 did not present an additive effect on BC dilation, indicating 
that the two compounds exerted their effect via the same MLCK enzyme target. However, CaM did not exert a 
protective effect against fasudil-induced dilation, indicating that fasudil did not act via MLCK, whereas bosentan 
combined with fasudil had an additive effect on BC dilation and resulted in a 1.89-fold (p = 0.01) increase in the 
Figure 8. Alteration of ROCK activity by the tested compounds. (A) Untreated and 20 μM Y-27632-treated 
cells. Phase-contrast images were captured after 3 h. F-actin was localized using a rhodamine-phalloidin 
fluoroprobe (red). Hoechst-labelled nuclei are shown in blue (bar = 30 μm). Note the BC dilation in the 
presence of Y-27632 cells. (B) ROCK activity after a 1-h treatment of HepaRG cells using a ROCK activity 
assay Kit (Millipore, catalogue CSA001). The data were expressed relative to that of the untreated cells and are 
represented as the means ± SEM of 3 independent experiments. *p < 0.05 compared with that of the untreated 
cells, #p < 0.05 compared with that of either CPZ (50 μM) or CsA (50 μM) alone.
www.nature.com/scientificreports/
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Figure 9. Alteration of MLC2 phosphorylation/dephosphorylation rhythms by the tested compounds.  
(A) Untreated and 20 mM BDM-treated HepaRG cells. Phase-contrast images were captured after 3 h. F-actin was 
localized using a rhodamine-phalloidin fluoroprobe (red). Hoechst-labelled nuclei are shown in blue (bar = 30 μm). 
(B) Representative western blots of the p-MLC2/total MLC2 forms at various time points. (C) Graphic representation 
of MLC2 phosphorylation/dephosphorylation quantified using ImageJ 1.48 software. The data were expressed in 
arbitrary units (A.U.) and represented as the means ± SEM of 3 independent experiments.
www.nature.com/scientificreports/
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Figure 10. Alteration of the MLCK pathway with the tested compounds. (A) HepaRG cells exposed to 20 μM 
ML-9 for 3 h and the controls: phase-contrast microscopy and F-actin localization (bar = 30 μm). Note the BC 
dilation in the presence of ML-9 cells. (B) Time-lapse imaging of HepaRG cells treated with ANIT, DCA, fasudil 
or bosentan alone, co-treated with 5 μM CaM; or treated with bosentan + ML-9 or fasudil (bar = 30 μm); BC: 
green arrows. (C) Quantification of the BC area using ImageJ 1.48 software as described in the Materials and 
Methods. The data were expressed as the fold change in the BC mean area after 3 h relative to the mean area at 
www.nature.com/scientificreports/
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mean area compared with the 1.48-fold and 1.47-fold increases with bosentan and fasudil alone, respectively. 
These results indicate that these compounds acted via distinct MLCK and ROCK enzymatic targets (Fig. 10B,C).
Discussion
Cholestasis is a complex multifactorial disease with distinct characteristics. However, its main feature is its fre-
quent association with abnormal BA elimination. Many authors have attempted to predict drug-induced cholesta-
sis based on direct inhibition of the major canalicular BA transporters. Unfortunately, this approach is poorly 
predictive because many cholestatic drugs do not directly interfere with BA canalicular efflux transporters25–28. In 
the current work, we took advantage of metabolically competent human HepaRG and primary hepatocyte cells 
to demonstrate that drug-induced cholestasis was strongly associated with the deformation and motility failure 
of BC. In addition, we provided the first demonstration that the ROCK/MLCK pathway plays a critical role in 
disrupting BC dynamic movements via cholestatic agents.
As observed in the liver in vivo29, we found that the biliary saccular lumen and tubular canaliculi structures 
were reformed in normal cultured hepatocyte monolayers, with biliary saccular lumen primarily occurring at 
bifurcations in the bile canalicular structures of HepaRG cells and CCHH and tubular BC occurring more fre-
quently in the primary hepatocytes maintained in a sandwich configuration. Moreover, the accumulation of 
F-actin fibres and specific localization of transporters and junctional proteins contributed to qualifying these 
characteristically polarized BC in both in vitro liver cell models30,31.
Biliary secretion is a complex process involving several steps, which include translocating BA across the baso-
lateral membrane and then trafficking through the cytoplasm, transporting across the canalicular membrane, and 
effluxing out of the canalicular lumen. The motility of BC was mainly demonstrated in isolated hepatocyte cou-
plets32 and has been reported to play a role in bile flow in rat hepatocytes both in vitro and in vivo33. For instance, 
it has been shown that interference in acto-myosin interactions by phalloidin, cytochalasin or lithocholic acid 
decreases the rate of spontaneous contractions of BC and reduces the flow of bile34–36. Herein, time-lapse micros-
copy was used to study human HepaRG and primary hepatocytes, and we observed contractions of BC charac-
terized by repeated opening and closing processes as well as the unidirectional expulsion of what appeared to be 
bile products from the S-BC to a proximal small T-BC. Importantly, the contractions appeared to be essential 
for the clearance of BAs. TA loading resulted in an increased frequency of BC contractions accompanied by the 
increased efflux activity of TA, which is a strong evidence that these contractions have a role in bile flow23. The 
electron microscopy observations of neighbouring BC with different sizes also supported the occurrence of BC 
contractions.
One important observation of the present work was that BC motile activity was rapidly inhibited by exposure 
to various cholestatic compounds. By performing a comparative analysis of the 6 compounds, our study showed 
that BC could be deformed early depending on the tested compounds. Thus, for the first time, two main classes 
of cholestatic drugs could be distinguished, one that includes CPZ and CsA and induces canalicular lumen con-
striction and another that includes fasudil, ANIT, DCA and bosentan and induces canalicular lumen dilation. 
Interestingly, both classes of cholestatic drugs were associated with strong impairments of contractile movements. 
Under similar experimental conditions, the two non-cholestatic hepatotoxic drugs paracetamol and amiodarone 
did not cause obvious BC alterations (not shown). Noticeably, BC constriction as observed with CPZ and CsA 
might represent severe effects related to the induction of oxidative and endoplasmic reticulum stress at high drug 
concentrations, which ultimately lead to cell death as previously reported18,19. Further investigations of a large 
series of cholestatic and non-cholestatic drugs are needed to identify the mechanisms underlying these irrevers-
ible effects.
A failure of bile secretion fundamentally defines cholestatic disease and is associated with morphological and 
contractile disorders. Three main observations support the occurrence of bile secretion failure. i) Abnormal intra-
cellular accumulation of [3H]-TA in the presence of CPZ and CsA as well as with fasudil, DCA and bosentan. This 
accumulation was dose-dependent regardless of whether these drugs constricted or dilated the canalicular lumen, 
and similar results have been reported with CPZ and CsA18–20, while this is the first description of the adverse 
outcome induced by the widely-used drug fasudil. ii) Concomitant markedly diminishment of BA clearance as 
indicated by the efflux of fluorescent NBD-UDCA in the presence of CPZ and fasudil. However, these deformed 
BC (constricted or dilated) appeared as inert cisternae without the ability to undergo dynamic contractions and 
opening in a rhythmic manner to discharge their contents, which was observed in the control BC. This result 
supports the hypothesis that impaired contractile movements of canalicular lumens are critical for clearance 
deficiencies. iii) Impairment of the compensatory feedback control of BA clearance in the presence of cholestatic 
drugs, which was shown with TA loading.
Because the functional basis of BC contraction/relaxation dynamics is mediated by actin filaments, cholestatic 
drugs would be expected to alter contractile movements, and this led us to identify the molecular mechanisms 
controlling myosin ATPase activity, which is a key step in the development of acto-myosin-based contractile 
forces. Motor myosin II activity is mainly controlled by phosphorylation of its light chain. Therefore, we investi-
gated the two classes of enzymes, MLC kinases and Rho-kinases, which are known to be the major kinases that 
T0 (means ± SEM of 3 independent experiments). *p < 0.05 compared with that of the untreated cells, #p < 0.05 
compared with that of the cultures treated with either ANIT, DCA or bosentan alone. &p < 0.05 compared with 
that of the cultures treated with both bosentan and fasudil. (D) [3H]-TA clearance in HepaRG cells treated 
with bosentan and DCA alone or co-treated with CaM for 2 h. The data were expressed relative to that of the 
untreated cells arbitrarily set at 100% and are presented as the means ± SEM of 3 independent experiments. 
*p < 0.05 compared with that of the untreated cells, #p < 0.05 compared with that of the cultures treated with 
either bosentan or DCA alone.
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phosphorylate MLC in vitro and in vivo37,38. This work provides the first evidence that the ROCK/MLCK pathway 
and its associated enzymes are major targets of the cholestatic compounds that lead to deformation of the apical 
lumen and impairment of contractile movements. This conclusion is supported by the following evidence: (i) 
time-dependent alternations of MLC2 phosphorylation/dephosphorylation states in untreated cells were coor-
dinated with the contraction frequency of BC; (ii) TA treatment increased the frequency of BC contractions 
and MLC2 phosphorylation/dephosphorylation and also increased the clearance of radiolabelled [3H]-TA; (iii) 
activation of ROCK activity was observed as early as 1 h after exposure to either CsA or CPZ and maintained an 
abnormally high MLC2 phosphorylation level; (iv) prevention of CsA- and CPZ-induced activation of ROCK 
by fasudil; (v) rapid, drastic and permanent MLC2 dephosphorylation leading to BC dilation by the stable and 
potent ROCK inhibitor fasudil; (vi) reduction of MLC2 phosphorylation by DCA, ANIT and bosentan, which 
was similar to that of fasudil although to a lower extent, and abrogation of the phosphorylation/dephosphoryla-
tion dynamics by targeting Ca2+/CaM-dependent MLCK instead of ROCK; and (vii) regulation of BC by actin via 
a contribution of the myosin II heavy chain ATPase as indicated by the effect of BDM, an inhibitor of this enzyme, 
which clearly mimicked MLCK and ROCK inhibitors by inducing BC dilation, thereby making this enzyme 
another potential signalling target for cholestatic compounds.
In summary, our work demonstrates that spontaneous rhythmic contractions of BC are essential for bile flow. 
These contractions are correlated with the rhythm of MLC2 phosphorylation/dephosphorylation. By targeting 
distinct regulators of the ROCK/MLCK/myosin pathway, cholestatic compounds with diverse chemical struc-
tures and therapeutic properties can induce alterations in the contractile movements of BC and impairments in 
the secretion of BA (Fig. 11). This study highlights new insights into the mechanisms underlying the disruption 
of BA secretion and identifies new potential predictive biomarkers for drug-induced cholestasis.
Materials and Methods
Reagents. Cyclosporine A (CsA), chlorpromazine (CPZ), deoxycholic acid (DCA), 2,3-butan-
edione monoxime (BDM), 1α -naphthyl isothiocyanate (ANIT), methylthiazoletetrazolium (MTT), 
4-(1-Aminoethyl)-N-(4-Pyridyl) cyclohexanecarboxamide dihydrochloride (Y-27632), 1-(5-Chloronaphthalene-
1-sulfonyl)-1H-hexahydro-1,4-diazepine hydrochloride (ML-9), taurocholic acid (TA) and 5 (and 6)-car-
boxy-2,7-dichlorofluorescein diacetate (CDFDA) were purchased from Sigma (St. Quentin Fallavier, France). 
Rho-associated kinase (ROCK) activity assay Kit was from Merck Millipore (Fontenay sous Bois, France). 
3α -hydroxy-7-nitrobenzoxadiazolyl-ursodeoxycholic acid (NBD-UDCA) fluorescent analogue was a gift from 
Pr A. F. Hoffmann (San Diego, USA). Fasudil (HA-1077) was purchased from BPS Bioscience (Le Perray En 
Yvelines, France). Bosentan was obtained from Sequoia Research Products (Pangbourne, U.K.). Calmodulin 
Figure 11. Schematic representation of the main molecular targets of the tested cholestatic compounds 
in the ROCK/MLCK pathway. (1) CsA and CPZ induced the activation of ROCK activity and maintained 
abnormally high MLC2, thereby leading to BC constriction. However, (2) fasudil and Y-27632 inhibited ROCK 
activity and caused MLC2 dephosphorylation, thereby leading to BC dilation. (3) DCA, ANIT, bosentan and 
ML-9 inhibited Ca2+/CaM-dependent MLCK instead of ROCK and led to BC dilation. (4) BDM inhibited 
myosin II heavy chain ATPase activity and disrupted acto-myosin interaction causing BC dilation. ROCK, 
Rho-kinase; Ca2+, calcium; CaM, calmodulin; MLCK, myosin light chain kinase; MLCP, myosin light chain 
phosphatase; MLC, myosin light chain; BC, bile canaliculi.
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(CaM) was from Merck Chemicals (Fontenay sous Bois, France). Phalloidin fluoprobe was purchased from 
Interchim (Montluçon, France). [3H]-Taurocholic acid ([3H]-TA) was from Perkin Elmer (Boston, MA, USA). 
Specific antibodies against Phospho-Myosin Light Chain 2 (Ser19) (diluted 1:1000, catalog 3675), total MLC2 
(diluted 1:1000, catalog 8505) were purchased from Cell Signalling Technology (Schuttersveld, Netherlands). 
Anti-multidrug-resistance-protein 1 (MDR1) (diluted 1:50, catalog 517310) was obtained from Calbiochem 
(Saint Aubin, France). Anti-zona occludens protein 1 (ZO-1) (diluted 1:500, catalog 610966) antibody was 
obtained from BD Biosciences (Le Pont de Claix, France). Anti-MRP2 (1:200, catalog 3373) antibody was from 
Abcam (Cambridge, UK). Secondary antibodies (diluted 1:500) were purchased from Invitrogen (Saint Aubin, 
France). Hoechst dye was from Promega (Madison, WI, USA). Other chemicals were of reagent grade.
Cell cultures. HepaRG cells were seeded at a density of 2.6 × 104 cells/cm2 in Williams’ E medium supple-
mented with 2 mM glutamax, 100 U/mL penicillin, 100 μg/mL streptomycin, 10% HyClone foetal calf serum, 
5 μg/mL insulin, and 50 μM hydrocortisone hemisuccinate. At confluence (after 2 weeks), the HepaRG cells were 
shifted to the same medium supplemented with 1.7% dimethyl sulfoxide for 2 additional weeks to obtain conflu-
ent differentiated cultures containing equal proportions of hepatocyte-like and progenitor/primitive biliary-like 
cells39,40. These differentiated hepatic cell cultures were used for the analytical assays.
Human hepatocytes were obtained from Biopredic International (St Gregoire, France), who holds all permits 
required for the acquisition and transformation of human biological materials to be used in research (AC-2007-43/ 
law CSP L1245-2/IE-2011-566). Informed consents were obtained from all subjects (Center of Biological Resources, 
Rennes, France, BB-0033-00,056). Research protocols were performed in accordance with French legal guidelines 
(French Ministery of Health). All the experimental protocols with human hepatocytes were approved by the local 
institutional committee (Pontchaillou Hospital, Rennes, France). The hepatocytes were isolated by collagenase per-
fusion of histologically normal liver fragments from 4 adult donors undergoing resection for primary and second-
ary tumours. The primary cultures were obtained by hepatocyte seeding at a density of 1.5 × 105 cells/cm2 onto 
collagen-precoated plates in Williams’ E medium supplemented as detailed above except for the addition of 10% 
foetal calf serum and 1 μg/ml bovine serum albumin. The medium was discarded 12 h after cell seeding, and the 
cultures were then maintained in the same medium as for the HepaRG cells and designated as conventional cultured 
HH (CCHH), or maintained for 24 to 48 h and then washed with cold medium and overlaid with matrigel at a con-
centration of 0.25 mg/mL in ice-cold Williams’ E medium for the preparation of sandwich cultured HH (SCHH). 
The medium of both the CCHH and SCHH preparations was renewed daily. The CCHH and SCHH were prepared 
from the same donors and analysed in parallel. The SCHH cultures were used after at least a 3 day-matrigel overlay.
Immunolabelling. The cells were washed with warm phosphate buffered saline (PBS), fixed with either meth-
anol for 15 min at − 20 °C or with 4% paraformaldehyde for 20 min, and then washed three times with cold PBS. 
After paraformaldehyde fixation, the cells were permeabilized for 20 min with 0.3% Triton X-100 in PBS followed 
by a 1 h incubation in PBS containing 1% bovine serum albumin and 5% normal donkey serum. The cells were 
then incubated overnight with primary antibodies directed against MDR1, MRP2 and ZO-1 and diluted in PBS 
containing 1% bovine serum albumin and 5% normal donkey serum. After washing with cold PBS, the cells were 
incubated for 2 h with mouse or rabbit Cy® 5 -labelled secondary antibodies (excitation/emission: 649/670 nm). 
Finally, the cells were again washed with cold PBS and incubated with a rhodamine-phalloidin fluoroprobe SR101 
(200 U/ml) (excitation/emission: 540/565 nm) diluted at 1/100 for F-actin labelling for 20 min41. The nuclei were 
labelled with 5 ng/ml Hoechst dye (excitation/emission: 346/460 nm). Immunofluorescence images were captured 
using a Cellomics ArrayScan VTI HCS Reader (Thermo Scientific, Waltham, MA, USA).
BC area quantification. The BC area quantification was based on ZO-1 protein immunolabelling and 
phase-contrast images.
ZO-1 immunolabelling. After capturing the ZO-1 protein immunofluorescence images, the BC were quantified 
using the Cell Health Profiling V4 bio application of the ArrayScan software (Thermo Scientific). Segmentation 
was performed by adjusting the shape, area and brightness parameters to eliminate non-corresponding objects. 
Based on their areas (labelled objects), the BC were classified into 3 categories: 20–50, 50–100 and > 100 μm2 
(Supplementary Fig. 1). An analysis was performed on 10 images per condition.
Phase-contrast images. The mean BC areas were determined from 3 zones per condition using ImageJ 1.48 
software at T0 and after 3 h of compound exposure. Briefly, after capturing the time-lapse images, bright objects 
corresponding to BC were segmented by adjusting the shape and area parameters to exclude non-corresponding 
objects. The data are presented as the fold change in the BC mean area after 3 h relative to their mean area at T0.
Electron microscopy. HepaRG cells were fixed by the addition of 2.5% glutaraldehyde for 30 min. After fix-
ation, the specimens were rinsed with 0.2 M Na cacodylate buffer and post-fixed with 2% osmium tetroxide for 
30 min. After further rinsing, the samples were dehydrated, infiltrated with a mixture of acetone-eponate (50/50) 
and embedded in DMP30-Eponate. Ultrathin sections were examined with a JEOL 100CX II electron microscope42.
Western blotting analysis of MLC2 phosphorylation. The HepaRG cells were treated with the 6 tested 
compounds for different time points (0–225 min), washed with cold PBS, and finally suspended in cell lysis buffer 
supplemented with protease and phosphatase inhibitors (Roche, Mannheim, Germany). Aliquots containing an 
equivalent total protein content as determined by the Bradford procedure with bovine serum albumin as the 
standard were subjected to sodium dodecyl sulfate/12% polyacrylamide gel electrophoresis, electrotransferred to 
Immobilon-P membranes, and incubated overnight with primary antibodies directed against p-MLC2 and total 
MLC2 (dilution: 1/1000). After exposure to a horseradish peroxidase conjugated anti-mouse/rabbit antibody 
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(dilution: 1/5000) (Dako, Les Ulis, France), the membranes were incubated with a chemiluminescence reagent 
(Millipore, Billerica, MA, USA) and the bands were then visualized with Fusion-Capt software (Vilber Lourmat, 
Marne La Vallée, France) and quantified using ImageJ 1.48.
CDF clearance. The cells were washed with warm Williams’ E medium without phenol red and incubated in 
3 μM CDFDA for 30 min at 37 °C in the same medium used for passive intracellular accumulation. Upon hydrol-
ysis by the intracellular esterases, CDFDA was converted to fluorescent CDF (excitation/emission: 488/509 nm) 
and directed towards the biliary pole by membrane transporters, particularly MRP2. Then, after washing, the cells 
were treated with the 6 compounds for 2 and 3 h and imaging was performed using a Cellomics ArrayScan VTI 
HCS Reader (Thermo Scientific).
NBD-UDCA clearance. The cells were washed with warm Williams’ E medium without phenol red and 
incubated in 5 μM NBD-UDCA (excitation/emission: 488/509 nm) for 30 min at 37 °C in Williams’ E medium 
without phenol red. NBD-UDCA is secreted into BC by membrane transporters, mainly BSEP43. Then, after 
washing, the cells were treated with the 6 compounds for 2 h and imaging was performed using an inverted 
microscope (Zeiss Axiovert 200M and AxioCam MRm).
Taurocholate acid clearance. To investigate the effect of the compounds on TA clearance from the cell 
layer, the cells were first exposed to 43.3 nM [3H]-TA for 30 min to induce its intracellular accumulation, washed 
with standard buffer and then incubated with the tested compounds for 2 h in a standard buffer containing Ca2+ 
and Mg2+. After incubation, the cells were washed and scraped in 0.1 N NaOH, and the remaining radiolabelled 
substrate was measured through scintillation. [3H]-TA clearance was determined based on its accumulation in 
the cell layers (cells + BC) and calculated relative to the control using the following formula: [3H]-TA clear-
ance = [3H]-TA accumulation in (cells + BC)Control/[3H]-TA accumulation in cell layerTested compound  * 100.
Time-lapse cell imaging. Phase-contrast images of the HepaRG cells, CCHH and SCHH were captured 
every minute using time-lapse phase-contrast videomicroscopy. An inverted microscope (Zeiss Axiovert 200 M) 
was equipped with a thermostatic chamber (37 °C and 5% CO2) to maintain the cells under normal culture con-
ditions. The images were captured with an AxioCam MRm camera.
BC dynamics analysis. Contraction/relaxation activity and the opening/closing rhythm of BC (spikes) were 
evaluated by time-lapse cell imaging and quantified by a software video analysis and a modelling tool (Tracker 
4.87). Briefly, circular frames delimiting S-BC and the connections S-BC/T-BC were manually designed using the 
free hand selection tool of Tracker 4.87 to track and record brightness variations. These records reflected the area 
of S-BC and spikes at the connections between S-BC and T-BC (Supplementary Fig. 2).
ROCK activity. ROCK activity was measured with a Rho-associated kinase activity assay Kit (Millipore, 
catalogue CSA001) according to the manufacturer’s protocol with certain modifications. Briefly, HepaRG cells 
were treated with the tested compounds. After 1 h, the cells were lysed with a lysis buffer supplemented with 
anti-protease, and then 50 μL of the lysate was deposited in 96-well multi-strip plates pre-coated with MYPT1 
supplied with 10 mM DTT, 2 mM MgCl2 and 10 mM ATP for 60 min at 30 °C. An anti-phospho-MYPT1 (Thr696) 
antibody was added for 1 h, and then goat anti-rabbit IgG HRP secondary antibody was added for another 1 h, 
and chromogenic substrate tetra-methylbenzidine (TMB) was added for 15 min. Absorbance at 450 nm reflected 
the relative amount of ROCK activity in the sample, which was evaluated relative to the total protein content of 
each sample.
Cell viability. Cytotoxicity was evaluated by the MTT colorimetric assay. Briefly, the cells were seeded in 
96-well plates and treated with various concentrations of the compounds in triplicate for 4 h. After removing the 
medium, 100 μl of serum-free medium containing MTT (0.5 mg/ml) was added to each well and incubated for 2 h 
at 37 °C. The water-insoluble formazan was dissolved in 100 μl dimethyl sulfoxide, and absorbance was measured 
at 550 nm.
Statistical analysis. A one-way ANOVA with a multiple comparison test (GraphPad Prism 5.00) was per-
formed to compare the data. Each value corresponded to the mean ± SEM of three independent experiments. 
Data were considered significantly different at p < 0.05.
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